This month effective altruism has gotten lots of attention, including a cover story in The Economist. It feels pretty surreal to be on the receiving end of it. But I feel grateful these ideas have caught on, and even more grateful for the drive, earnestness, and compassion of so many people who took strange but well-argued ideas seriously and then actually acted on them....
We’re the co-founders of Better Futures Guide (BFG), a charity evaluator specifically focused on livelihoods. We were founded last year through Ambitious Impact’s Charity Entrepreneurship Incubation Program. We welcome questions, criticism and opportunities for collaboration, in the comments or at info@betterfuturesguide.org.
...
By Alexander Berger, Chris Smith and Aaron Roesch
Earlier this year, Nan Ransohoff, head of Public Goods at Stripe, published a viral[1] blog post about the coming third wave of American philan...
New anti-malaria treatment clears phase 3 trials.
I just found that there is a new anti-malarial alternative to artemisinin, the most common antimalarial chemical, which has successfully completed Phase 3 trials. Its nickname is GanLum and apparently has quite powerful effects:
This is an important advance because resistance to artemisinin is one of the growing concerns in the fight against malaria.
You may read more in https://www.npr.org/sections/goats-and-soda/2025/11/12/g-s1-97487/malaria-drug-new and https://www.mmv.org/newsroom/news-resources-search/phase-3-trial-next-generation-malaria-treatment-ganaplacide-lumefantrine .
Very interesting! And very hopeful! Thanks for sharing!